Table 5. Low-Risk Disease (Stages I–IIA; No Bulky Disease; No B Symptoms)
| Chemotherapy (No. of Cycles)a | Radiation (Gy) | Stage | No. of Patients | Event-Free Survival (No. of Years of Follow-up) | Survival (No. of Years of Follow-up) |
| VAMP (4) [41] | IFRT (15–25.5) | CS I/IIb | 110 | 89% (10) | 96% (10) |
| VAMP (4) [49] | IFRT (25.5) | CS I/IIb | 41 | 88% (5) | 100% (5) |
| None | 47 | 89% (5) | |||
| COPP/ABV (4) [14,17] | IFRT (21) | CS IA/B, IIAc | 94 | 100% (10)d | 97% (10)d |
| None | 113 | 89% (10)d | 96% (10)d | ||
| OEPA/OPPA (2) [18] | IFRT (20–35) | I, IIA | 281 | 94% (5) | N/A |
| None | 113 | 97% (5) | |||
| ABVE (2-4) [43] | IFRT (25.5) | IA, IIA, IIIA1 | 51 | 91% (6) | 98% (6) |
| CS = clinical stage; IFRT = involved-field radiation therapy; N/A = not applicable; No. = number. | |||||
| aRefer to Table 4 for more information about the chemotherapy regimens. | |||||
| bWithout bulky mediastinal (defined as one-third or more of intrathoracic ratio measured on an upright posteroanterior chest radiograph) or peripheral lymphadenopathy (defined as 6 cm or more) or B symptoms. | |||||
| cWithout adverse features, defined as one or more of the following: hilar adenopathy, involvement of more than four nodal regions; mediastinal tumor with diameter equal to or larger than one-third of the chest diameter, and node or nodal aggregate with a diameter larger than 10 cm. | |||||
| dResults from as-treated analysis. |
References
- Nachman JB, Sposto R, Herzog P, et al.: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 (18): 3765-71, 2002. [PUBMED Abstract]
- Wolden SL, Chen L, Kelly KM, et al.: Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. J Clin Oncol 30 (26): 3174-80, 2012. [PUBMED Abstract]
- Dörffel W, Lüders H, Rühl U, et al.: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 215 (3): 139-45, 2003 May-Jun. [PUBMED Abstract]
- Donaldson SS, Link MP, Weinstein HJ, et al.: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 25 (3): 332-7, 2007. [PUBMED Abstract]
- Tebbi CK, Mendenhall NP, London WB, et al.: Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer 59 (7): 1259-65, 2012. [PUBMED Abstract]
- Metzger ML, Weinstein HJ, Hudson MM, et al.: Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA 307 (24): 2609-16, 2012. [PUBMED Abstract]
